Lu Xiao-Li, Liu Si-Sun, Xiong Zhen-Fang, Wang Fen, Li Xia-Ying, Deng Huan
Sanxiang Hospital Zhongshan, China.
The First Affiliated Hospital of Nanchang University Nanchang, China.
Int J Clin Exp Pathol. 2020 Jan 1;13(1):14-20. eCollection 2020.
The underlying mechanisms of chemoresistance-induced recurrence of ovarian carcinoma are largely unknown. The purpose of this study was to investigate the clinical significance of RAD51C and its role in ovarian tumorigenesis and progression.
60 cases of ovarian epithelial tumors (30 benign and 30 malignant tumors, respectively) were enrolled from 2014 to 2016. Immunohistochemistry was used to evaluate RAD51C expression in tumor tissues, and RT-PCR was employed to test RAD51C mRNA levels in SKOV3, A2780, and CAOV3 cell lines. Targeted knockdown of RAD51C was achieved with siRNA to explore the changes of cell proliferation, migration, and apoptosis.
RAD51C protein level in carcinoma tissues, especially in the high-grade group (P<0.001), was significantly higher than that of benign tumors and associated with pathological type, stage, and overall survival (P<0.05). Downregulation of RAD51C promoted apoptosis and decreased cell survival rate and migration.
Our results supported that RAD51C contributes to the progression of ovarian carcinoma, suggesting its promising application as an independent prognostic marker for diagnosis and treatment.
化疗耐药导致卵巢癌复发的潜在机制在很大程度上尚不清楚。本研究旨在探讨RAD51C的临床意义及其在卵巢肿瘤发生和进展中的作用。
选取2014年至2016年60例卵巢上皮性肿瘤（分别为30例良性肿瘤和30例恶性肿瘤）。采用免疫组织化学法评估肿瘤组织中RAD51C的表达，应用逆转录聚合酶链反应检测SKOV3、A2780和CAOV3细胞系中RAD51C的mRNA水平。通过小干扰RNA靶向敲低RAD51C，以探讨细胞增殖、迁移和凋亡的变化。
癌组织中RAD51C蛋白水平，尤其是高级别组（P<0.001），显著高于良性肿瘤，且与病理类型、分期及总生存期相关（P<0.05）。RAD51C表达下调可促进细胞凋亡，降低细胞存活率和迁移能力。
我们的结果支持RAD51C促进卵巢癌进展，提示其作为诊断和治疗的独立预后标志物具有应用前景。
